In December, Howard Marks published an investment memo titled, “Is it a bubble?” that expressed some of his skepticism and reservations about artificial intelligence and the stock-market boom it had ...

Howard Marks is much less skeptical about AI than he was just a few months ago. In December, Howard Marks published an investment memo titled, "Is it a bubble?" that expressed some of his skepticism ...

NEW YORK, Jan. 27, 2026 /PRNewswire/ -- August today announced a two-week free trial to its platform and August Academy, a comprehensive library of over 100 video tutorials and lessons designed to ...

Self-serve platform removes traditional barriers of cost, implementation, and training that have kept powerful AI tools out of reach for most legal practices NEW YORK, Jan. 27, 2026 /PRNewswire/ -- ...

Vor Biopharma (VOR) rose ~17% on Tuesday after J.P. Morgan initiated its coverage with an Overweight recommendation and a Dec. 2026 price target of $43, citing a potential blockbuster status for the ...

Vor Biopharma Inc. (VOR) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting ...

I love being a licensed private pilot. As you may have seen from other videos, I am starting my instrument rating training. I really believe that I will be a much safer pilot when I get my IFR or ...

Vor Bio has handed Dallan Murray a swift return to the workforce. Weeks after being let go by Sarepta Therapeutics, Murray has landed the chief commercial officer post in Vor’s new-look C-suite.

Vor Biopharma, a cancer cell therapy developer that laid off nearly all of its employees in a wind down of operations last month, has reemerged with new management, an in-licensed lead drug candidate, ...